MRI Lymph Node Evaluation for Prediction of Metastases in Rectal Cancer

KARIN ALMLÖV¹, MISCHA WOISETSCHLÄGER², PER LOFTÅS³,
OLOF HALLBÖÖK³, NILS O. ELANDER⁴ and PER SANDSTRÖM³

¹Department of Biomedical and Clinical Sciences, Division of Surgery, Linköping University, Norrköping, Sweden;

²Department of Radiology, Department of Medical and Health Sciences,

and Center for Medical Image Science and Visualization, Linköping University, Linköping, Sweden;

³Department of Biomedical and Clinical Sciences, Division of Surgery, Linköping University, Linköping, Sweden;

⁴Department of Biomedical and Clinical Sciences, Division of Oncology, Linköping University, Linköping, Sweden

Abstract. Aim: To explore whether the size and characteristics of the largest regional lymph node in patients with rectal cancer, based on magnetic resonance imaging (MRI), following neoadjuvant therapy and before surgery, is able to identify patients at high risk of developing metachronous metastases. Patients and Methods: A retrospective case-control study with data from the Swedish Colo-Rectal Cancer Registry. Forty patients were identified with metachronous metastases (M+), and 40 patients without metastases (M0) were matched as controls. Results: Patients with M+ disease were more likely to have a regional lymph node measuring ≥ 5 mm than patients with M0. (87% vs. 65%, $p=0.02$). There was also a significant difference between the groups regarding the presence of an irregular border of the largest lymph node (68% vs. 40%, $p=0.01$). Conclusion: Lymph nodes measuring ≥ 5 mm with/without displaying irregular borders at MRI performed after neoadjuvant therapy emerged as risk factors for metachronous metastases in patients with rectal cancer. Intensified follow-up programmes may be indicated in these patients.

Rectal cancer is a global health problem, each year affecting 700,000 new individuals worldwide (1). In Sweden, a total of 2,000 patients are diagnosed with rectal cancer annually; morbidity and mortality remain high, with a 5-year relative survival of 66% (2).

This article is freely accessible online.

Correspondence to: Karin Almlöv, Kirurgiska Kliniken, Vrinnevisjukhuset, SE-601 82 Norrköping, Sweden. E-mail: karin.almlov@liu.se

Key Words: MRI, rectal cancer, lymph node, neoadjuvant therapy, metastases, follow-up.

Approximately 20-30% of all patients with rectal cancer will, at some point, be diagnosed with metastases (3-5) in the liver, lungs or elsewhere. Fifty percent of these are diagnosed as synchronous metastases, *i.e.* simultaneous with the diagnosis of the primary rectal tumour (6). In the other half, metastases are metachronous; the metastases develop later, *i.e.* during follow-up of the primary treatment. Despite improved therapeutic options with combination chemotherapy, stereotactic radiotherapy, surgical resections and locally ablative approaches, a significant proportion of these patients will die due to their disease. In Sweden, the relative 5-year survival in patients with stage IV rectal cancer (*i.e.* metastatic disease) is 20% (6). According to the Swedish Registry of Liver, Bile duct and Gallbladder Cancer (Sweliv), relative 5-year survival in patients with colorectal liver metastasis undergoing resection or ablation is 51% (7). This indicates that active follow-up and prompt initiation of treatment upon detection of metastases is relevant and may lead to long-term remission or even cure. The risk of developing metastases is proportional to the primary cancer stage. In rectal cancer, this is most evident for liver metastases (5).

In order to identify patients with recurrent or metastatic disease as early as possible, there is a Swedish national standardised follow-up programme after rectal cancer surgery. Several attempts have been made to find evidence of improved survival with more intense follow-up programmes for colorectal cancer (8, 9). The COLOFOL trial (8) did not find a significant reduction of 5-year mortality when comparing high-frequency follow-up to low-frequency. A Cochrane review from 2016 concluded that more patients in a high-frequency follow-up were treated with surgery (with curative intent) (10). This might indicate that optimal follow-up programmes need to be more individualised than today. Preferably, such tailored follow-up strategies should use simple and easily available tools for prognostic risk scoring. The vast majority of patients with rectal cancer will undergo

MRI for tumour staging and evaluation of neoadjuvant therapy, and a natural starting point would therefore be the identification of early MRI radiological warning signs that indicate a higher risk of metachronous metastasis and that a more intense follow-up might be required.

The importance of MRI in staging rectal cancer is widely recognised, as is the use of MRI for assessment of tumour response after neoadjuvant treatment. Neoadjuvant treatment in rectal cancer consists of radiation therapy (RT) with or without chemotherapy (11). In lymph node staging (N-stage), size, signal intensity and border contours are different criteria for indicating positivity (12-15). Current European guidelines for restaging, updated in 2018, consider all nodes <5 mm to be benign, and ≥5 mm to be malignant (15).

Due to the effect of RT on lymph nodes, nodal status following neoadjuvant therapy is difficult to interpret (16). Since RT eradicates both benign and malignant lymph nodes (17), there are fewer nodes to evaluate post RT. Size does more accurately predict positive lymph nodes after RT compared to before it (18, 19). This might possibly make interpretation easier for a non-expert radiologist to evaluate the lymph node status after RT. The size of the largest lymph node might be a criterion for use in a clinical setting.

In a previous study by our group, we reported that the average size of the largest lymph node on evaluating MRI was significantly larger in the group with nodal metastases (N+) than in that without (N0) (20). Other studies have made node-per-node-analyses in order to find lymph nodes with metastasis (12, 21).

To explore the importance and reliability of a standardised lymph node predictive model based on the preoperative MRI, a retrospective case-control study was designed. Patients with rectal cancer and evidence of metachronous metastasis during follow-up were compared with matched controls who had similar baseline characteristics but who did not develop metachronous metastases. The main hypothesis was that if the largest lymph node after neoadjuvant treatment was ≥5 mm, or had other morphological characteristics signifying involvement of cancer, it would indicate a higher risk for development of metachronous metastasis.

Patients and Methods

According to Swedish national guidelines (22), all patients with rectal cancer should be assessed at multidisciplinary team conferences (MDT). An MRI is performed before the MDT in order to stage the rectal tumour. The most advanced rectal tumours are treated with preoperative RT or chemo-radiotherapy (CRT). Short-course RT, 5×5 Gy, is directly followed by surgery or with a 6-14-week delay before surgery. Long-course RT, 2×25 or 1.8×28 Gy, is also followed by a waiting period before surgery, to allow for RT-induced down-staging of primary tumour and regional lymph nodes. Short-course RT with delay gives biological effect and oncological

Table I. Baseline characteristics of patients with rectal cancer with (M+) or without (M0) metachronous metastasis. Clinical lymph node stage (cN) was analysed using Fisher's exact test.

	All	M+	M0	p-Value
All	80	40	40	
Gender				
Female	32	16	16	>0.99
Male	48	24	24	
Age at diagnosis, years				
Median (range)	66 (33-80)	66 (33-80)	67 (38-78)	0.43
cT				
cT3	40	20	20	>0.99
cT4	40	20	20	
cN				
cN0	10	3	7	0.14
cN1-2	67	34	33	
cNX	3	3	0	

cT: Clinical stage of tumour.

Table II. Radiotherapy (RT), and neoadjuvant and adjuvant treatment.

	All	M+*	M0	p-Value
Short course RT, n	13	7	6	0.72
Long course RT, n	66	32	34	
Neoadjuvant chemotherapy, n (%)	70 (88)	36 (90)	34 (85)	0.50
Adjuvant chemotherapy, n (%)	36 (45)	23 (56)	13 (32)	0.03

*For one patient, it was impossible to ascertain the RT treatment.

results equal to those of long-course RT with delay (23, 24), and can be regarded as comparable therapies. When RT is followed by a delay, it is common practice to perform an MRI after 6 weeks, ahead of surgery, in order to rule out progression. Thus, two MRI examinations are performed before surgery.

The inclusion criteria for this study were patients with rectal cancer, without synchronous metastases (cM0), who had undergone elective radical surgery (R0) during 2008-2015, in the south east region of Sweden covering three centres (Jönköping, Kalmar and Östergötland) and a total population of 1.1 million (2019) (25). All participants were evaluated with preoperative MRI, received neoadjuvant (C)RT with radical surgery delayed more than 6 weeks, and subsequently developed one or more metachronous metastases.

Metachronous metastases were defined as one or more metastases found after rectal surgery in patients who were staged as M0 at MDT. Metastases were defined as metastases in the liver, lungs or another organ. The medical records were reviewed after a minimum follow-up period of 2 years from surgery. Some patients had died by the time medical records were reviewed; these patients were also included in the study.

In order to compare this group of metastasis-afflicted patients, an equally large number of metastasis-free patients meeting the inclusion criteria were identified and included. This control group

Figure 1. Magnetic resonance imaging showing the irregular border of the largest lymph node.

was matched to the study group by gender, county of residence, year of surgery, age at diagnosis, type of RT, neoadjuvant chemotherapy, T-stage and adjuvant chemotherapy (Tables I and II). Node-per-node analyses were not made, since the objective was to study MRI in a clinical setting.

Patients. The patients were identified from the Swedish Colo-Rectal Cancer Registry (SCRCR). Sweden is unique in that all Swedish citizens since 1947 have a personal identity number (26). Since 1995, all patients with rectal cancer have been recorded in the SCRCR (27).

To ensure that no metastases were missed in the SCRCR, data from Sweliv and the Swedish Registry of Thoracic Surgery (ThoR) were also collected. These patients were compared to SCRCR and if uncertainties were detected, these were resolved by a manual review of the primary medical record. No additional patients were found in these two registries. All data collection was made in 2017 and 2018, and the medical records were examined in May 2018.

MRI interpretation and analyses. The MR images were collected from different Radiology Departments. The MR images were

assessed by one radiologist (M.W.) with 5 years of experience in reading pelvic MRI and was aware of the inclusion criteria but blinded to the information on metastasis, as well as the surgical and pathological findings. The interpreter had no access to the primary report of the MRI examinations. Analysis was performed using a Sectra Workstation IDS7 with diagnostic monitors.

The field strength of all examinations was 1.5 Tesla. The examination protocol varied as the examinations were carried out at different locations. The assessment was performed on axial, sagittal and oblique T2-weighted sequences in at least two planes as well as T1-weighted images. Eighty-seven percent of the examinations included a thin-slice sequence with 3 mm slice thickness. Thirteen percent of the examinations had a slice thickness of 5 mm. The T1-weighted images were mainly used for the assessment of lymph nodes. Diffusion-weighted images were not assessed as these were not available for all patients.

The following parameters were evaluated (28) for this study: Tumour stage (T- stage), number of lymph nodes (total number of lymph nodes, both potentially benign and malignant were recorded), short axis diameter of the largest lymph node (mm), borders of the largest lymph node (regular/irregular), and signal characteristics of the largest lymph node (regular/irregular) (Figure 1).

Statistical analysis. Baseline characteristics are presented as the median and range when not otherwise stated, using independent median sample test; when presented as the mean, the standard deviation is also presented. Parametric data were analysed using Student's *t*-test and non-parametric data were analysed using Pearson's chi-squared test. A *p*-value of less than 0.05 was considered significant. The analyses were made using SPSS®, version 25 (IBM, Armonk, NY, USA).

Ethics. This study was approved by the Regional Ethics Committee at Linköping University (Dnr 2017/425-31) and conducted according to national/European regulations and the Helsinki declaration. Informed consent was not necessary given the retrospective non-interventional nature of the study.

Results

The initial cohort consisted of 703 patients who were identified in the SCRCR and diagnosed with rectal cancer between January 2008 and December 2015. Of these, a total of 138 (19.6%) patients were found to have been diagnosed with metachronous metastases, of whom 40 had been examined with a preoperative MRI. The number of individuals eligible for inclusion in the study was therefore 40 patients, and thus 40 patients were also allocated to the control group (Table I).

The sparse use of MRI was partly due to the fact that a majority of these patients had received short-course RT without delay to surgery (which does not justify a second MRI preoperatively), and partly because some centres had yet to implement the MRI procedure as standard practice in their clinical settings at the time of data entry.

The median follow-up time between primary surgery and medical record review was 53 (range=29-117) months. The attrition rate was 45%, due to death of included patients.

Demographics. The median number of positive lymph nodes was significantly higher in patients with metachronous metastases compared to those without [2 (range=0-19) vs. 0 (range=0-7), *p*<0.001]. There was no significant difference between the groups regarding classification of mucinous tumours at histopathological assessment (six in the M+ group and eight in the M0 group, *p*=0.73). Distant metastatic sites were identified as the liver in 14, lungs in 20 and other (*e.g.* peritoneum and brain) in 11.

Median survival from primary surgery to death/date of medical record review was 28 (range=2-98) months in the M+ group and 53 (range=3-117) months in the M0 group (*p*<0.0001).

The median metastasis-free interval (from date of surgery to detection of metachronous metastasis) was 8 (range=1-31) months. Fourteen (35%) patients with metachronous metastases were treated with surgery (with curative intent), the remainder were treated with best supportive care, with or without palliative oncological therapies. Median survival from diagnosis of metastasis was 17 (range=1-61) months.

Table III. *Magnetic resonance imaging interpretation after neoadjuvant radiotherapy. Clinical stage of tumour after neoadjuvant treatment (yT) was analysed using Fisher's exact test.*

yT Stage	All	M+	M0	<i>p</i> -Value
yT1-2, n	19	7	12	0.37
yT3, n	55	29	26	
yT4, n	6	4	2	

MRI interpretation: Size of the largest lymph node. There were no significant differences between the M+ and M0 groups regarding the size of the largest lymph node (median 6 mm and 5 mm, respectively, *p*=0.35) or T-stage on evaluation of the MRI after neoadjuvant radiotherapy (Tables III and IV). However, there was a significant difference between the two groups regarding the number of patients with the largest lymph node ≥5 mm (n=34, 87% vs. n=26, 65%, *p*=0.02).

Lymph nodes larger than 8 mm were found only in patients with positive nodes on the histopathological assessment (n=13).

Morphology of the largest lymph node. Irregular borders of the largest lymph node were significantly more frequent in the M+ group [27 (68%)] compared with the M0 group [16 (40%)] (*p*=0.01) (Table IV).

Morphology of the largest lymph node compared to histopathological assessment. When comparing the histopathological lymph node assessment (ypN) with the MRI-assessment (ycN), there was a significant difference in the presence of irregular borders on MRI: With 25/38 (66%) in the ypN+ group and 18/42 (43%) in the ypN0 group (*p*=0.04). The frequency of heterogeneous signal was also significantly higher in the ypN+ group at 27/38 (71%) than in the ypN0 group [19/42 (45%)] (*p*=0.02).

Discussion

This study was conducted to explore the prognostic impact of lymph node characteristics on the preoperative MRI evaluation in patients with rectal cancer who had received neoadjuvant RT. Nodal status post neoadjuvant treatment was based on interpretation of the size, border characteristics and signal intensity of the largest lymph node. Our main finding was a positive association between the size of the largest lymph node (≥5 mm as measured on preoperative MRI) and the risk of developing metachronous metastases (*p*=0.02). Similarly, irregular border features of the largest lymph node were more common in the metastases group in this patient cohort (*p*=0.01). These results suggest the need

Table IV. Characteristics of the largest lymph node (LLN) after neoadjuvant radiotherapy.

	M+	M0	All	p-Value
Median diameter of LLN (range), mm	6 (3-14)	5 (2-28)	6 (2-28)	0.35
Largest lymph node ≥ 5 mm, n (%)	34 (87%)	26 (65%)	60 (76%)	0.02
Irregular border, n (%)	27 (68%)	16 (40%)	43 (54%)	0.01
Heterogenous signal intensity, n (%)	26 (65%)	20 (50%)	46 (56%)	0.18

for further studies focusing on standardised evaluation of the largest lymph node on the preoperative MRI as a tool for risk stratification and personalised follow-up schedules.

In a previous study by our group, the size of the largest lymph node after neoadjuvant treatment was found to indicate nodal positivity (20). In that study, lymph nodes of 8 mm or more in diameter were similarly correlated with ypN+. This confirmed, in accordance with other studies, that size is a key factor when interpreting MRI post RT in patients with rectal cancer (15, 18, 19).

As several studies have indicated, the MRI characteristics of lymph nodes in rectal cancer is also important for predicting nodal involvement (12, 13). This study supports these findings, since there were significant differences when comparing nodal status on histopathological assessment with characteristics of the largest lymph node on MRI.

Although the evidence is conflicting (8-10), the rationale for follow-up programmes is that early (rather than late) detection of metachronous metastases will lead to better treatment options due to less extensive disease, and therefore an enhanced likelihood for successful treatments and improved survival. As only a small proportion of patients will develop metachronous metastases, identifying risk factors would be of great value in order to find high-risk patients, and develop individualised follow-up programmes for them. In addition, other patients with very low risk of metastatic disease could be excluded from intense follow-up; economical costs as well as patient inconvenience and psychological stress associated with the follow-up schedule would therefore also be avoided. There are still questions regarding the optimal follow-up regime (8, 9), as several large multi-centre studies did not show any survival benefits between different follow-up-regimes (8-10). Case mix may hide any benefit of more intense follow-up in a sub-group of patients.

Apart from standardised and correct staging of the primary tumour, which has been recognised as a key prognostic parameter (4), the present results suggest that the size and characteristics of the largest lymph node on post neoadjuvant MRI might be a predictor for subsequent development of metachronous metastases, and a potential tool for future decisions regarding individualised follow-up.

The present study has some limitations. While the original cohort of patients was large at 703, of which 138 were

diagnosed with metachronous metastases during follow-up, a large proportion of these, 98 in fact, could not be included in the study. The reason for this is partly because the majority of the patients were treated with short-course RT without delay to surgery but also due to the absence of a preoperative MRI. The most likely explanation for absence of MRI after RT with delay was the delayed implementation of MRI in the post neoadjuvant/preoperative setting at many centres, a procedure that is now considered a standard of care (22). In effect, there were only 40 cases available for analysis, and groupwise or further multivariable statistics were not feasible. The matched case-control design, with minimal variation in other known prognostic parameters obscuring the factors of interest, was therefore considered the most sensible way to address the main hypothesis. There was a high attrition rate in median follow-up, due to high rate of death, these were thus censored. They were, however, included in the study. Due to the limitations mentioned, the results obtained should be interpreted with care. Nevertheless, the present findings encourage larger retrospective and prospective observational studies where the prognostic impact of standardised post neoadjuvant/preoperative MRI is further evaluated. The main strength of the present study was the population-based real-world approach and, given the Swedish public healthcare system that offers equal treatment and follow-up programmes to all citizens, this minimises the risk for bias based on socioeconomic factors and varying accessibility to healthcare providers.

In conclusion, this study indicates that both irregular lymph node border and largest lymph node size ≥ 5 mm, as measured on MRI post neoadjuvant treatment and before surgical resection, may be predictors for metachronous metastatic disease in rectal cancer. Further studies are needed to elucidate whether intensified follow-up programmes are beneficial or not in this group of patients.

Conflicts of Interest

None of the Authors have any conflicts of interest to report.

Authors' Contributions

All Authors of this research article directly participated in the planning, execution, or analysis of this study. All Authors read and approved the final version submitted.

References

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68: 394-424, 2018. PMID: 30207593. DOI: 10.3322/caac.21492
- The National Board of Health and Welfare, The Swedish Cancer Society. Cancer i siffror 2018. Available at: <https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/statistik/2018-6-10.pdf> (Last accessed 25 March 2019).
- van der Geest LG, Lam-Boer J, Koopman M, Verhoef C, Elferink M and de Wilt JH: Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. *Clin Exp metastasis* 32: 457-465, 2015. PMID: 25899064. DOI: 10.1007/s10585-015-9719-0
- Elferink MA, de Jong KP, Klaase JM, Siemerink EJ and de Wilt JH: Metachronous metastases from colorectal cancer: A population-based study in North-East Netherlands. *Int J Colorectal Dis* 30: 205-212, 2015. PMID: 25503801. DOI: 10.1007/s00384-014-2085-6
- Riihimäki M, Hemminki A, Sundquist J and Hemminki K: Patterns of metastasis in colon and rectal cancer. *Sci Rep* 6: 2-9, 2016. PMID: 27416752. DOI: 10.1038/srep29765
- The Swedish Colo-Rectal Cancer Registry. Rektalcancer 2017, Nationell kvalitetsrapport från Svenska Kolorektalcancerregistret. Available at: https://www.cancercentrum.se/globalassets/cancerdiagnoser/tjock--och-andtarm-anal/kvalitetsregister/tjock-och-andtarm-fr-2018/rektalrapport_2017.pdf (Last accessed 25 March 2019).
- The Swedish Registry of Liver, Bile duct and Gallbladder Cancer (Sweliv). Cancer i lever och gallvägar. Årsrapport nationellt kvalitetsregister, 2019. Diagnosår: 2018. Available at: https://www.cancercentrum.se/globalassets/cancerdiagnoser/lever--och-galla/kvalitetsregister/sweliv_rapport_2019_final.pdf (Last accessed 20 February 2020).
- Wille-Jørgensen P, Syk I, Smedh K, Laurberg S, Nielsen DT, Petersen SH, Renehan AG, Horvath-Puho E, Pålman L and Sørensen HT: Effect of more vs less frequent follow-up testing on overall and colorectal cancer-specific mortality in patients with stage II or III colorectal cancer. The COLOFOL randomized clinical trial. *JAMA* 319: 2095-2103, 2018. PMID: 29800179. DOI: 10.1001/jama.2018.5623
- Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, George S and Mant D: Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: The FACS randomized clinical trial. *JAMA* 311: 263-270, 2014. PMID: 24430319. DOI: 10.1001/jama.2013.285718
- Jeffery M, Hickey BE, Hider PN and See AM: Follow-up strategies for patients treated for non-metastatic colorectal cancer. *Cochrane Database Syst Rev* 11: CD002200, 2016. PMID: 27884041. DOI: 10.1002/14651858.CD002200.pub3
- Moreno CC, Sullivan PS and Pardeep KM: MRI evaluation of rectal cancer: Staging and restaging. *Curr Probl Diagn Radiol* 46: 234-241, 2017. PMID: 28089690. DOI: 10.1007/s00261-015-0394-z
- Brown G, Richards CJ, Bourne MW, Newcombe RG, Radcliffe AG, Dallimore NS and Williams GT: Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. *Radiology* 227: 371-377, 2003. PMID: 12732695. DOI: 10.1148/radiol.2272011747
- Kim JH, Beets GL, Kim MJ, Kessels AG and Beets-Tan RG: High-resolution MR imaging for nodal staging in rectal cancer: Are there any criteria in addition to the size? *Eur J Radiol* 52: 78-83, 2004. PMID: 15380850. DOI: 10.1016/j.ejrad.2003.12.005
- Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, Quirke P, Sebag-Montefiore D, Moran B, Heald R, Guthrie A, Bees N, Swift I, Pennert K and Brown G: Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY Experience. *J Clin Oncol* 29: 3753-3760, 2011. PMID: 21876084. DOI: 10.1200/JCO.2011.34.9068
- Beets-Tan RG, Lambregts DMJ, Maas M, Bipat S, Barbaro B, Curvo-Semedo L, Fenlon HM, Gollub MJ, Gourtsoyianni S, Halligan S, Hoeffel C, Kim SH, Laghi A, Maier A, Rafaelsen SR, Stoker J, Taylor SA, Torkzad MR and Blomqvist L: Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. *Eur Radiol* 28: 1465-1475, 2018. PMID: 29043428. DOI: 10.1007/s00330-013-2864-4
- Kim DJ, Kim JH, Lim JS, Yu JS, Chung JJ, Kim MJ and Kim KW: Restaging of rectal cancer with MR imaging after concurrent chemotherapy and radiation therapy. *Radiographics* 30: 503-516, 2010. PMID: 20228331. DOI: 10.1148/rg.302095046
- Patel UB, Blomqvist LK, Taylor F, George C, Guthrie A, Bees N and Brown G: MRI after treatment of locally advanced rectal cancer: How to report tumor response – the MERCURY experience. *Am J Roentgenol* 199: 486-495, 2012. PMID: 22997398. DOI: 10.2214/AJR.11.8210
- Kim I, Kang J, Lim BJ, Sohn SK and Lee KY: The impact of lymph node size to predict nodal metastasis in patients with rectal cancer after preoperative chemoradiotherapy. *Int J Colorectal Dis* 30: 459-464, 2015. PMID: 25586204. DOI: 10.1007/s00384-014-2099-0
- Heijnen LA, Maas M, Beets-Tan RG, Berkhof M, Lambregts DM, Nelemans PJ, Riedl R and Beets GL: Nodal staging in rectal cancer: Why is restaging after chemoradiation more accurate than primary nodal staging? *Int J Colorectal Dis* 31: 1157-1162, 2016. PMID: 27055660. DOI: 10.1007/s00330-014-3231-9
- Loftås P, Sturludóttir M, Hallböök O, Almlöv K, Arbmán G and Blomqvist L: Assessment of remaining tumour involved lymph nodes with MRI in patients with complete luminal response after neoadjuvant treatment of rectal cancer. *Br J Radiol* 91: 20170938, 2018. PMID: 29668301. DOI: 10.1259/bjr.20170938
- Zhou J, Zhan S, Zhu Q, Gong H, Wang Y, Fan D, Gong Z and Huang Y: Prediction of nodal involvement in primary rectal carcinoma without invasion to pelvic structures: Accuracy of preoperative CT, MR, and DWIBS assessments relative to histopathologic findings. *PLoS One* 9: e92779, 2014. PMID: 24695111. DOI: 10.1371/journal.pone.0092779
- Regional Cancer Centres (RCC). Tjock- och ändtarmscancer, nationellt vårdprogram. RCC, 2016 Available at: https://www.cancercentrum.se/globalassets/cancerdiagnoser/tjock--och-andtarm-anal/vardprogram/nvpkolorektalcancer_2016-03-15.pdf (Last accessed 25 March 2019).
- Erlandsson J, Holm T, Pettersson D, Berglund Å, Cedermark B, Radu C, Johansson H, Machado M, Hjern F, Hallböök O, Syk I,

- Glimelius B and Martling A: Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): A multicentre, randomised, non-blinded, phase 3, non-inferiority trial. *Lancet Oncol* 18: 336-346, 2017. PMID: 28190762. DOI: 10.1016/S1470-2045(17)30086-4
- 24 Cisel B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, Cencelewicz A, Spatek M, Polkowski W, Jankiewicz M, Styliński R, Bębenek M, Kapturkiewicz B, Maciejczyk A, Sadowski J, Zygułska J, Zegarski W, Jankowski M, Las-Jankowska M, Toczko Z, Żelazowska-Omiotek U, Kępką L, Socha J, Wasilewska-Tesluk E, Markiewicz W, Kładny J, Majewski A, Kapuściński W, Suwiński R and Bujko K: Long-course preoperative chemoradiation *versus* 5×5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: Long-term results of the randomized Polish II study. *Ann Oncol* 30: 1298-1303, 2019. PMID: 31192355. DOI: 10.1093/annonc/mdz186
- 25 SCB. Folkmängd i riket, län och kommuner 31 mars 2019 och befolkningsförändringar 1 januari-31 mars 2019. Available at: <https://www.scb.se/hitta-statistik/statistik-efter-amne/befolkning/befolkningens-sammansattning/befolkningsstatistik/pong/tabell-och-diagram/kvartals--och-halvarsstatistik--kommun-lan-och-riket/kvartal-1-2019/> (Last accessed 17 December 2019)
- 26 Ludvigsson JF, Otterblad-Olausson P, Pettersson BU and Ekblom A: The Swedish personal identity number: Possibilities and pitfalls in healthcare and medical research. *Eur J Epidemiol* 24: 659-667, 2009. PMID: 19504049. DOI: 10.1007/s10654-009-9350-y
- 27 Pahlman L, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjödaahl R, Ojerskog B, Damber L and Johansson R: The Swedish Rectal Cancer Registry. *Br J Surg* 94: 1285-1292, 2007. PMID: 17661309. DOI: 10.1002/bjs.5679
- 28 Radiology Assistant. Rectal Cancer - MR Staging 2.0. Available at: <http://www.radiologyassistant.nl/en/p56195b237699d/rectal-cancer-mr-staging-20.html> (Last accessed 1 Aug 2018).

Received March 8, 2020

Revised April 9, 2020

Accepted April 13, 2020